BioSpace News Archive

Transnetyx, Inc. announced today its collaboration with One Codex on an end-to-end microbiome sequencing and analysis service

Fulfilling a commitment to diversity and inclusion in the Phase 3 COVE Study of the Moderna COVID-19 Vaccine, Moderna enlisted the help of TrialScope, the global leader in clinical trial disclosure and transparency technology, for patient recruitment. Moderna utilized TrialScope Connect, an industry-first patient

Invacare Corporation (NYSE: IVC) (“Invacare” or the “company”) announces that it will release its financial results for the fourth quarter and year ended December 31, 2020, after the market closes on Wednesday, February 10, 2021.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced presentation of data from a Phase 1b/2a pilot study highlighting three patients who received pemziviptadil (PB1046)

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2020 financial results will be released on Wednesday, February 10, 2021 after the markets close.

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will present at the Virtual Investor Conference Small and Microcap Showcase on February 4, 2021.

Resverlogix Corp. (“Resverlogix”, or the “Company”) (TSX:RVX) announces that it has postponed the webcast and conference call, previously scheduled for January 28 th , 2021, by one week to February 4 th , 2021 at 10:00 am MT.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2020. Quarter ended December 31, 2020 Highlights ─ compared to December 31, 2019 Net sales of $140.1 million decreased $7.5 million.

Medicure Inc. (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the early completion of iSPASM, a randomized, double-blind, single-center, Phase 1/2a trial aimed at assessing the safety of long-term (7-day) use of AGGRASTAT ®

It has been estimated that the global electrosurgical generators market would record a valuation of $2.5 billion by 2025 end, perhaps due to the massive demand for various surgeries, given the rising cases of orthopedic injuries and road accidents around the globe.